Abstract
Comparison of Biologic Agents in the Treatment of Psoriatic Arthritis: A Network Meta-Analysis of Efficacy and Safety
Author(s): Mia Turner*Psoriatic arthritis (PsA) is a chronic inflammatory arthritis that often coexists with psoriasis, leading to significant morbidity. The advent of biologic therapies has revolutionized the management of PsA, but the comparative efficacy and safety of different biologic agents remain unclear. This network meta-analysis evaluates data from 25 randomized controlled trials to compare the efficacy and safety profiles of tumor necrosis factor (TNF) inhibitors, interleukin-12/23 inhibitors, and interleukin-17 inhibitors in PsA treatment. The results demonstrate that IL-17 inhibitors have a superior efficacy in achieving minimal disease activity and improving quality of life, while TNF inhibitors remain the most widely used class due to their established safety and efficacy profile.